Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

CAPLACIZUMAB vs CAPMATINIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

CAPLACIZUMAB vs CAPMATINIB: Safety Overview

Metric CAPLACIZUMAB CAPMATINIB
Total FAERS Reports 145 2,301
Deaths Reported 34 583
Death Rate 23.4% 25.3%
Hospitalizations 53 388
Average Patient Age 53.0 yrs 71.9 yrs
% Female Patients 51.2% 53.9%
FDA Approval Date N/A May 6, 2020
Manufacturer Genzyme Corporation Novartis Pharmaceuticals Corporation
Route N/A ORAL
Marketing Status N/A Prescription